Drug profile · INN
lidocaine hydrochloride
LIDOCAINE HYDROCHLORIDE
lidocaine hydrochloride (LIDOCAINE HYDROCHLORIDE) is a sodium channel alpha subunit blocker. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: intradermal. Current US regulatory status: approved.
Drug details — lidocaine hydrochloride
- US status
- approved
- Class
- —
- Route
- INTRADERMAL
- Patents
- 0
- Programs
- 9
- Data quality
- 0.89
Quick answer
lidocaine hydrochloride (LIDOCAINE HYDROCHLORIDE) is a sodium channel alpha subunit blocker. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: intradermal. Current US regulatory status: approved.
Key facts
Mechanism of action
Sodium channel alpha subunit blocker
Primary target: Sodium channel alpha subunit
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is lidocaine hydrochloride?
lidocaine hydrochloride (LIDOCAINE HYDROCHLORIDE) is a sodium channel alpha subunit blocker. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: intradermal. Current US regulatory status: approved.
What is the brand name for lidocaine hydrochloride?
LIDOCAINE HYDROCHLORIDE is a marketed brand name for lidocaine hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of lidocaine hydrochloride?
lidocaine hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.